All posts by CAC2

Assorted news from last week: Save the Date:  CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. The World Health Organization (WHO) has published the consensus of a set of indicators to evaluate and monitor the development of palliative care worldwide. The report was presented last week at the 17th Palliative Care World Congress in a joint symposium of the WHO and the European Association for Palliative Care. Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness, according to data published in The Lancet Oncology. Furthermore, deaths due to the infection were proportionally higher […]

Read more

Assorted news from last week: CAC2 Ethics Think Tank will present a paper entitled Cultivating Ethically Sustainable Relationships with Stakeholders When Non-Profits Fund Pediatric Cancer Clinical Trials at SIOP 2021 (on Saturday, October 23rd). The National Childhood Cancer Registry (NCCR) issued an update this week of frequently requested incidence statistics based on the International Classification of Childhood Cancer (ICCC) using data from . It includes number of cases, age-adjusted incidence rates, and trends by characteristics including single age at diagnosis, sex, race/ethnicity, period of diagnosis, and cancer site and subsites.  The report contains data on 232,859* tumors in children under age […]

Read more

Assorted news from last week: The FDA has granted a rare pediatric disease designation (RPDD) to lutetium-177(177Lu)-omburtamab-DTPA for use as a potential therapeutic option in pediatric patients with medulloblastoma, according to an announcement from CAC2 Member Y-mAbs Therapeutics, Inc.,  developer of the product. Cancers in children, adolescents and young adults can be resistant to medical treatments or recur even when initial treatments appear successful.  Findings of a 10-year study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and in collaboration with the Beat Childhood Cancer Research Consortium, suggest that deeper genomic analysis and therapies […]

Read more

Assorted news from last week: CAC2 Member Mary Beth Collins, highlights the importance of Childhood Cancer License Plates, how they amplify awareness efforts, the advocacy required to create these plates and CAC2’s Childhood Cancer License Plate awareness effort. Gavin Lindberg had an Opinion Piece published in The Washington Post titled “The US Should Invest in Children’s Health.” From the New England Journal of Medicine correspondence: Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma Mount Sinai researchers have developed a therapy that shows promise against acute myeloid leukemia. A new study based on patient samples collected over the past decade by [...] Read more

Assorted news from the last two weeks: In recognition of Childhood Cancer Awareness Month, NCI Director Ned Sharpless reflected on the progress that’s been made against cancers that largely affect children. New Jersey established the “Pediatric Cancer Research Fund” and an advisory board within the New Jersey State Commission on Cancer Research for disbursement of monies deposited in the fund and provides voluntary contributions by taxpayers on gross income tax returns for pediatric cancer research. Additionally, S3724 appropriates $5 million to the New Jersey Pediatric Cancer Fund. A study of children with cancer identified an association between physical activity, fatigue, […]

Read more

Assorted news from the last week: This video abstract breaks down financial toxicity issues for families with special health care needs. Researchers have discovered that low-risk and high-risk neuroblastoma have different cell identities, which can affect the survival rate. Cisplatin, a chemotherapy drug known to cause hearing loss in children is more likely to do so the earlier in life children receive it, new UBC research has found. A new study of palliative care in pediatric oncology has found that non-White children were more likely to die in the hospital than White patients, but that the difference was in concordance with […]

Read more